Latest news with #ovariancancer
Globe and Mail
2 days ago
- Business
- Globe and Mail
Compugen's COM701 Trial: A New Hope for Ovarian Cancer?
Compugen ((CGEN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Compugen Ltd is currently recruiting participants for a clinical trial titled An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC). The study aims to assess whether COM701, an experimental antibody, can delay the progression of ovarian cancer and its safety profile. The trial is testing COM701, administered intravenously every three weeks, as both a standalone treatment and in combination with other anti-cancer drugs. The primary goal is to determine if COM701 can slow or stop cancer progression and delay the need for new treatments. This interventional study uses a randomized, parallel, triple-masked design. Participants are randomly assigned to receive either COM701 or a placebo, with a 67% chance of receiving the experimental drug. The primary purpose is treatment, and the study includes regular safety and efficacy reviews by a data monitoring committee. The study began on July 22, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on the same start date, indicating active recruitment and ongoing study activities. The successful development of COM701 could positively impact Compugen's stock performance by enhancing investor confidence in its pipeline. This trial's progress is crucial in the competitive oncology market, where innovative treatments are highly sought after. The study is ongoing, and further details can be accessed on the ClinicalTrials portal.
Medscape
2 days ago
- Health
- Medscape
Ovarian Cancer Risk Rises Soon After IBS Diagnosis
TOPLINE: Women with a new diagnosis of irritable bowel syndrome (IBS) have a significantly higher risk for ovarian cancer at 3 months and 6 months post-diagnosis, but this risk is no longer elevated beyond 8 months. METHODOLOGY: Ovarian cancer often presents with nonspecific symptoms overlapping those of IBS. The frequency of misdiagnosis remains unknown, and not all IBS guidelines recommend screening for ovarian cancer. Researchers conducted a retrospective cohort study using US administrative claims data to compare ovarian cancer incidence in adult women with and without a new IBS diagnosis. Diagnostic codes were used to identify cases of IBS and ovarian cancer. TAKEAWAY: The cohort comprised 9804 women with IBS and 79,804 women without IBS, identified between January 2017 and December 2020. Women with IBS had a significantly higher risk for ovarian cancer at 3 months (hazard ratio [HR], 1.71; P = .02) and 6 months (HR, 1.43; P = .02), but not beyond 8 months post-diagnosis. Women with both IBS and endometriosis had an even greater risk for ovarian cancer at 3 months (HR, 4.20; P = .01), 6 months (HR, 3.52; P = .01), and after 1 year (HR, 2.67; P = .04). Increasing age was significantly associated with higher ovarian cancer incidence only in women younger than 50 years (HR, 1.07; P < .01), regardless of IBS status. IN PRACTICE: 'Identifying patient-specific risk factors, such as chronic pelvic pain or endometriosis, could help develop tailored risk profiles and improve the approach to personalized care in women with IBS-type symptoms,' the authors wrote. SOURCE: This study was led by Andrea Shin, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles. It was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: The use of diagnostic codes for identifying IBS may have led to misclassification or reflected symptoms rather than confirmed and validated diagnosis. DISCLOSURES: This study received support from the National Institutes of Health. Some authors reported serving as consultants, advisors, and/or receiving research support from pharmaceutical and healthcare companies; one author reported having stock options. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
BBC News
4 days ago
- Entertainment
- BBC News
Warwickshire fundraiser Mr Ovary given British Citizen's Award
A man who dresses as a giant ovary to raise awareness and funds for ovarian cancer research has been honoured with an award for services to healthcare. Craig McMurrough, from Stratford-upon-Avon, Warwickshire, has completed more than 200 runs and events, including the London Marathon and Great North Run, wearing a giant foam ovary costume. He took up the challenge after his sister Cheryl died with ovarian cancer in 2016. "It's a beautiful tribute to my late sister," said Mr McMurrough of the was among 27 people given the British Citizen Award (BCA) at the Palace of Westminster on Thursday for their outstanding contributions to society. Mr McMurrough has raised close to £100,000 for cancer support charity Ovacome, and also created a choir for women with ovarian cancer."It feels wonderful to be awarded," he said. "It's a beautiful tribute to my late sister but also to all those other women we've lost to this terrible disease and those who continue to battle it," said Mr McMurrough. "Cheryl was simply an earth angel," he added. "She had the most caring, loving personality and everyone loved her - she did so much for others and was completely selfless, her bright blue eyes lit up a room and her infectious laugh meant you couldn't help but laugh and smile along with her."He said he hoped the award would give him the opportunity to spread awareness to an even wider audience."Cheryl's motto in life was never, never give up and I will continue to honour her memory every time I put my costume on," he said. Stephanie Wood from BCA partner One Stop said: "This year's medallists exemplify the incredible support within our communities, especially during challenging times."We're honoured to partner with the BCA and play a part in recognising these exceptional individuals." Follow BBC Coventry & Warwickshire on BBC Sounds, Facebook, X and Instagram.
Yahoo
6 days ago
- Business
- Yahoo
Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the . Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company specializing in cortisol modulation by developing compounds that antagonize the glucocorticoid receptor. Based in California, the company treats Cushing's syndrome with its commercial drug Korlym. The company advances a pipeline of over 30 clinical-stage molecules for endocrinology, oncology, metabolism, and neurology. On July 14, 2025, the company announced that it had filed for a new drug application to the U.S. FDA for relacorilant. Relacorilant is a selective cortisol modulator for treating platinum-resistant ovarian cancer. The submission follows the positive data from its pivotal Phase 3 ROSELLA and Phase 2 trials. The trials indicated that relacorilant combined with nab-paclitaxel offers improved progression-free and overall survival, without increasing the safety burden of the patients. Since platinum-resistant ovarian cancer currently has limited therapies, the FDA approval for relacorilant has high expectations. Amid this advancement in Corcept Therapeutics Incorporated (NASDAQ:CORT)'s relacorilant, Piper Sandler and H.C. Wainwright reiterated their Buy rating on the stock. Piper Sandler maintains a price target of $131 while H.C. Wainwright has set the price target at $145. With an impressive projected 5-year EPS growth of 69.48% and a low beta of 0.21, Corcept Therapeutics Incorporated (NASDAQ:CORT) promises an attractive investment for those seeking high growth at low risk. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
SBS Australia
18-07-2025
- Health
- SBS Australia
The final farewell isn't easy. This growing service helped Vibha and thousands like her
In a cosy apartment in Sydney's west, Vibha Gulati is looking at photos of her late mother, Bhusan. "She was an amazing person. She was very compassionate, very loving, very hospitable to people who came to the house." A migrant from India, Bhusan Gulati was 87 when she was diagnosed with a life-limiting illness. It was a terrible shock for Vibha who had lived with her mother for 35 years. "The doctors said she had ovarian cancer and that she had less about six months to live. It was shocking. It was really shocking. I was losing my best friend. We loved each other very much." After the diagnosis, Bhusan Gulati refused medical treatment and chose voluntary assisted dying at home in the care of her daughters, Prabha and Vibha. "It was important for her. She advocated for voluntary assisted dying. She wanted control over her death and the whole process of her illness. She did not want any chemo or radiation. Surgery was posed as an option, but that was also refused. She could manage herself quite well. She was just ill during the last week, she was going out to cafes restaurants till the week she passed away." Vibha Gulati says a mix of Buddhist, Hindu and spiritual beliefs helped to farewell her mother in December last year. "We had chanting here while she was passing away. So we had Indian chants, which are Indian mantras infused with spiritual energy. It creates a very calming effect on the mind and on the emotions as well." While faith has supported Vibha Gulati through her loss, the grief remains raw and is, at times, hard to bear. "My spiritual belief gives me strength, trust that I will meet her again and that she has not gone forever. I can feel her presence around me sometimes. So it's really, really lovely. But that loss is still there and I think it takes a lot of time to get used to." It's one reason she turned to an online support platform called the Violet Initiative, a national not-for-profit organisation that helps people navigate the last chapters of life. "I found out about Violet after she passed away and I had some counselling sessions online. The loss was great. It comes in waves so often that you think you're all right and then suddenly you'll be crying. I felt really understood by them. I felt they held the space very well to what I was going through. They didn't negate any feeling that I had." Vibha Gulati is not alone. In recent years more than 30,000 people have accessed the service. It offers guides and digital support, as CEO Melissa Reader explains. "We are really trying to help families and communities be more prepared around the last stages of a person's life. People come to us saying, 'I just don't know where to start. My mum is in her late eighties, dad might've died a couple of years ago. I'm usually the eldest daughter stepping into that caregiving role. I'm managing my own family, work, life, career and I'm completely overwhelmed'." As Australia's population ages services like Violet become more crucial. Caring for dying people in hospital already costs around $4 billion annually, according to Violet research. And Ms Reader says that figure will rise. "We have about 12,000 people turning 85 each year today. In five years there'll be a fivefold increase that'll be 60,000 people reaching that age each year. And our health and age care systems are at capacity today." More than 180,000 people die in Australia each year. Yet Ms Reader says few have prepared a will or left clear instructions about their end-of-life choices. "Up to 90 per cent of us want to be cared for at home for as long as possible with our family and our friends and everything that's familiar to us and the right services and supports. But that is not what's playing out today. So, we see people having at least four hospital admissions through the last 12 months, about 33 or 34 days, and we see one in two Australians dying in hospital. That is our least preferred place to die." Ms Reader knows first-hand about facing the loss of a loved one. She has raised three children since her husband died of cancer. He was just 39 years old. She hopes that Violet can provide the practical and personal guidance that she badly needed. "We were completely unprepared for Mauro's death. He died in intensive care. We were totally unprepared for it and it was a very clinical and impersonal experience and quite frightening for all of us, including him. This is not an easy stage of life. It's very complex, it's very emotional and there's a lot of uncertainty." Mitch Gibson is among Violet's 50 volunteer guides and as someone who has lived through grief and loss, she is proud to provide personal care and support for those struggling. "I was trying to run my own small business, a yoga studio, and then all of a sudden when my dad had just been diagnosed with dementia my life partner, Mark was diagnosed with stage four pancreatic cancer. And to say that my world flipped upside down is an understatement." That was 11 years ago and the eventual death of her partner led to a life-changing decision. "I was only 56 years old. And I decided I wanted to work as a grief and bereavement counsellor and care for people who were carers because I'd had lived experience. It was ideal. These are the conversations I want to be having. This is the help I want to be offering. I didn't ask for this to happen to me, but it did. And so I am now in that world as someone who has cared, so why not use that to help someone?" The Violet platform also has an AI-enabled digital companion which offers personalised support in multiple languages. Violet's Chief Product and Technology Officer Yaniv Bernstein explains: "What we have is a really clever, voice-based artificial intelligence agent that talks to people in the manner of a normal conversation. And this is based on thousands of hours of data that we have of experience that we have through our guided support program. People can have this conversation at any time. And what they then get is a real assessment of where they're at, what stage they're in, what their needs are." And those needs are growing. Violet Chair Kate Carnell says action is urgently needed. "We are sleepwalking into the century's biggest economic and social crisis right at the moment. What I think we need to focus on is ensuring that people in the final stage of life get the care and attention and the dignity that they want." As life expectancy continues to rise and the population ages, Ms Carnell says Initiatives like Violet are crucial. "Digital technology is fundamental to having an actual solution to this problem. One-on-one approaches are important, there's no doubt and Violet provides those, but giving people access to information and feedback 24-7 by trusted sources using digital technology and AI will allow all Australians affordable access to the information that they need. And that's what Violet's focusing on." Vibha Gulati and her mother Bhusan are among the few to plan their final farewell. Caring for her mother at home fulfilled her dying wish, she says. "She was very pleased with things, and gave her a sense of peace through the whole process. And also it gave her a sense of control of her own life, which is what she advocated for her whole life and it's how she lived and that's how she passed away." And Vibha Gulati has this advice for others. "Do what you think is best for you and your loved one and listen to your inner self and you'll know what's the best thing to do." Support is available through LifeLine on 13 11 14 or Griefline which provides confidential support on 1300 845 745 and via
